JP2002508923A - 心肥大において差示的に発現される遺伝子、ならびに処置および診断におけるそれらの使用 - Google Patents

心肥大において差示的に発現される遺伝子、ならびに処置および診断におけるそれらの使用

Info

Publication number
JP2002508923A
JP2002508923A JP2000520565A JP2000520565A JP2002508923A JP 2002508923 A JP2002508923 A JP 2002508923A JP 2000520565 A JP2000520565 A JP 2000520565A JP 2000520565 A JP2000520565 A JP 2000520565A JP 2002508923 A JP2002508923 A JP 2002508923A
Authority
JP
Japan
Prior art keywords
protein
nucleic acid
seq
group
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000520565A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002508923A5 (cg-RX-API-DMAC7.html
Inventor
リチャード エイ. シムケッツ,
デイビッド ジー. ロウエ,
Original Assignee
キュラジェン コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キュラジェン コーポレイション filed Critical キュラジェン コーポレイション
Publication of JP2002508923A publication Critical patent/JP2002508923A/ja
Publication of JP2002508923A5 publication Critical patent/JP2002508923A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0053—Oxidoreductases (1.) acting on a heme group of donors (1.9)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70585—CD44
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Compression Or Coding Systems Of Tv Signals (AREA)
JP2000520565A 1997-11-10 1998-11-10 心肥大において差示的に発現される遺伝子、ならびに処置および診断におけるそれらの使用 Pending JP2002508923A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6504897P 1997-11-10 1997-11-10
US60/065,048 1997-11-10
US09/189,618 1998-11-09
US09/189,618 US6610480B1 (en) 1997-11-10 1998-11-09 Treatment and diagnosis of cardiac hypertrophy
PCT/US1998/023953 WO1999024571A2 (en) 1997-11-10 1998-11-10 Differentially expressed genes in cardiac hypertrophy and their uses in treatment and diagnosis

Publications (2)

Publication Number Publication Date
JP2002508923A true JP2002508923A (ja) 2002-03-26
JP2002508923A5 JP2002508923A5 (cg-RX-API-DMAC7.html) 2006-03-02

Family

ID=26745148

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000520565A Pending JP2002508923A (ja) 1997-11-10 1998-11-10 心肥大において差示的に発現される遺伝子、ならびに処置および診断におけるそれらの使用
JP2006323823A Withdrawn JP2007135219A (ja) 1997-11-10 2006-11-30 通信システムにおけるビデオフレーム転送方法と装置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2006323823A Withdrawn JP2007135219A (ja) 1997-11-10 2006-11-30 通信システムにおけるビデオフレーム転送方法と装置

Country Status (6)

Country Link
US (1) US6610480B1 (cg-RX-API-DMAC7.html)
EP (1) EP1030916A2 (cg-RX-API-DMAC7.html)
JP (2) JP2002508923A (cg-RX-API-DMAC7.html)
AU (1) AU1395399A (cg-RX-API-DMAC7.html)
CA (1) CA2309360A1 (cg-RX-API-DMAC7.html)
WO (1) WO1999024571A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012506031A (ja) * 2008-10-17 2012-03-08 エフ.ホフマン−ラ ロシュ アーゲー 心不全の評価におけるビグリカンの使用

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875567B1 (en) 1997-11-10 2005-04-05 Genentech, Inc. Method of detecting cardiac hypertrophy through probe hybridization and gene expression analysis
WO2001013900A2 (en) 1999-08-24 2001-03-01 Medicure International Inc. Compositions for the treatment of cardiovascular diseases containing pyridoxal compounds and cardiovascular compounds
EP1311704A2 (en) * 2000-05-30 2003-05-21 Medigene AG Novel target genes for diseases of the heart
DE10126371A1 (de) * 2001-05-30 2003-02-27 Medigene Ag Verfahren zur Identifizierung von Substanzen gegen Herzmuskelzellen-Hypertrophie
WO2002103355A1 (fr) * 2001-06-18 2002-12-27 Takeda Chemical Industries, Ltd. Agents prophylactiques/remedes pour maladies cardiaques
WO2003006687A2 (en) * 2001-07-10 2003-01-23 Medigene Ag Novel target genes for diseases of the heart
ITMI20012205A1 (it) * 2001-10-22 2003-04-22 Nanorganics Llc Metodo e mezzi per l'identificazione precoce di rischi di scompenso cardiaco
US7482132B2 (en) 2001-12-13 2009-01-27 Sanofi-Aventis Deutschland Gmbh Method for determining the activity of ornithine decarboxylase and for identifying effectors of ornithine decarboxylase activity
DE10161412A1 (de) * 2001-12-13 2003-07-03 Aventis Pharma Gmbh Verfahren zur Bestimmung der Aktivität der Ornithin-Decarboxylase sowie zur Identifizierung von Effektoren der Ornithin-Decarboxylase-Aktivität
WO2003059948A1 (en) * 2002-01-15 2003-07-24 Medigene Ag Dilated cardiomyopathy associated gene-2 (dcmag-2): a cytoplasmatic inducer of sarcomeric remodeling in cardiomyocytes
ES2770067T3 (es) 2004-05-11 2020-06-30 Ncardia Ag Descubrimiento de fármacos basado en células diferenciadas in vitro
US20070179815A1 (en) * 2006-01-20 2007-08-02 Heartscreen America, Inc. Medical screening system and method
EP2046997A2 (en) * 2006-07-25 2009-04-15 Deutsches Krebsforschungszentrum A common gene expression signature in dilated cardiomyopathy
EP2912458B1 (en) 2012-10-24 2018-07-18 NYU Winthrop Hospital Non-invasive biomarker to identify subjects at risk of preterm delivery
KR20200109293A (ko) 2017-09-13 2020-09-22 프로제너티, 인크. 자간전증 바이오마커 및 관련된 시스템 및 방법
WO2021113710A1 (en) 2019-12-04 2021-06-10 Progenity, Inc. Assessment of preeclampsia using assays for free and dissociated placental growth factor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0755446T3 (da) * 1994-04-25 2007-01-29 Genentech Inc Cardiotrophin og anvendelser deraf
US5972693A (en) 1995-10-24 1999-10-26 Curagen Corporation Apparatus for identifying, classifying, or quantifying DNA sequences in a sample without sequencing

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012506031A (ja) * 2008-10-17 2012-03-08 エフ.ホフマン−ラ ロシュ アーゲー 心不全の評価におけるビグリカンの使用

Also Published As

Publication number Publication date
WO1999024571A3 (en) 1999-08-26
WO1999024571A2 (en) 1999-05-20
US6610480B1 (en) 2003-08-26
EP1030916A2 (en) 2000-08-30
JP2007135219A (ja) 2007-05-31
AU1395399A (en) 1999-05-31
CA2309360A1 (en) 1999-05-20

Similar Documents

Publication Publication Date Title
US6486299B1 (en) Genes and proteins predictive and therapeutic for stroke, hypertension, diabetes and obesity
US6610480B1 (en) Treatment and diagnosis of cardiac hypertrophy
CA2378985A1 (en) Atherosclerosis-associated genes
US20040167066A1 (en) Cleavage and polyadenylation complex of precursor mrna
AU1449500A (en) Genes and proteins predictive and therapeutic for renal disease and associated disorders
US7345158B2 (en) Actin related cytoskeletal protein “LACS”
US6306648B1 (en) Cyclin-C variants, and diagnostic and therapeutic uses thereof
US20020160499A1 (en) Human serine carboxypeptidase
US6875567B1 (en) Method of detecting cardiac hypertrophy through probe hybridization and gene expression analysis
AU2004223739B2 (en) Cyclic AMP response element activator proteins and uses related thereto
AU2003203787B2 (en) Differentially Expressed Genes in Cardiac Hypertrophy and their uses in Treatment and Diagnosis
AU2006225276A1 (en) Differentially Expressed Genes in Cardiac Hypertrophy and their uses in Treatment and Diagnosis
US6825034B2 (en) Human RRN3 and compositions and methods relating thereto
WO2003062410A2 (en) Torero protein
JP2004528822A (ja) 筋特異的筋節カルシニューリン結合タンパク質(カルサルシン)に関する方法および組成物
US20060264610A1 (en) Protein complexes of the tip60 transcriptional activator protein
US20030119024A1 (en) Genes and proteins associated with T cell activation
WO1997043415A1 (en) Cyclin d binding factor, and uses thereof
WO1997043415A9 (en) Cyclin d binding factor, and uses thereof
WO2002064770A1 (fr) Nouvelle proteine de classe a du type recepteur eboueur
JP2001228146A (ja) 疾患関連遺伝子の用途
US20030148381A1 (en) More protein-protein interactions in the inner ear
JP2004532619A (ja) 細胞内シグナル伝達カスケードに関与する新規なヒト遺伝子ret16の同定およびクローニング
JP2001204480A (ja) 新規タンパク質およびそのdna
WO2002046420A2 (en) Nebulin-related protein

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20040728

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20040728

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080911

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090312